research Intermolecular NH 2 -/Carboxyl-terminal Interactions in Androgen Receptor Dimerization Revealed by Mutations That Cause Androgen Insensitivity
Mutations at Val-889 and Arg-752 disrupt key interactions in androgen receptor dimerization.
Search
forProducts matching "nonsteroidal androgen receptor antagonist"
Tracking 2 products like 259 Pyrilutamide (KX-826) Solution – 30ml 5mg/ml and 262 Pyrilutamide KX-826 Powder – 500mg from by companies like Anageninc. View all 2 products »
Sort by
Research
930-960 / 1000+ resultsresearch Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5α-reductase inhibitor
Combining 5α-reductase and aromatase inhibitors may better reduce estrogen levels.
research Synthesis of mimics of steroid A ring as potential enzyme inhibitors
Mimicking the steroid A-ring may help create effective enzyme inhibitors for prostate disease treatment.
research Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro
Clascoterone may be an effective topical treatment for hair loss.
research 5α‐Reductase Inhibitors
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
research Effect of testosterone and its antagonists on knee range of motion through RXFP1 and RXFP2 regulation in rat model (911.12)
Testosterone reduces knee movement, while flutamide and finasteride increase it.
research Clascoterone as a novel treatment for androgenetic alopecia
Clascoterone may be a promising treatment for hair loss.
research Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study
The inhibitor affects androgen metabolism but not ovarian function.
research 1343 Efficacy of asymmetric siRNA targeting androgen receptor for the treatment of androgenetic alopecia
cp-asiAR may effectively treat hair loss by targeting androgen receptors.
research Inhibition of Human Steroid 5β-Reductase (AKR1D1) by Finasteride and Structure of the Enzyme-Inhibitor Complex
Finasteride helps treat hair loss and prostate enlargement by blocking a specific enzyme.
research Androgen receptor: A promising therapeutic target in breast cancer
The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
research Silencing the androgen receptor: New skills for antiandrogen oligonucleotide skin and hair therapy
Targeting androgen receptors with antiandrogen oligonucleotides could effectively treat hair loss.
research 5α-Reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives
Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
research Androgen Receptor Blockade Induces the Phagocytosis of MRSA and Pseudomonas aeruginosa by Monocyte-Derived Macrophages In Vitro
Blocking androgen receptors boosts macrophages' ability to clear certain bacteria.
research Low-Dose Dimethyl Sulfoxide (DMSO) Suppresses Androgen Receptor (AR) and Its Splice Variant AR-V7 in Castration-Resistant Prostate Cancer (CRPC) Cells
Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
research Slow progress in prostate cancer
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
research Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer
SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
research Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia
New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.
research Cardiovascular Toxicities of Androgen Deprivation Therapy
ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
research Hormonal manipulation of benign prostatic hyperplasia
Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
research Generation of comparative pharmacophoric model for steroidal 5α-reductase I and II inhibitors: A 3D-QSAR study on 6-azasteroids
The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.
research Ruolo dei neurosteroidi nella modulazione dopaminergica
Neurosteroids help control dopamine responses in the brain.
research Anti-Androgenicity of Flutamide and its Metabolite Sch 16423
Flutamide and its metabolite can effectively reduce androgen effects.
research Effects of Finasteride (MK-906), a 5α-Reductase Inhibitor, on Circulating Androgens in Male Volunteers*
Finasteride safely lowers DHT levels without affecting testosterone.
research Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Breast cancer treatments work better with AR activation, improving results and reducing side effects.
research Control of androgen receptor expression in human keratinocytes and in a reconstituted human epidermis model with selective antisense oligonucleotides
Antisense oligonucleotides can reduce androgen receptor levels in skin cells, suggesting potential for treating skin disorders.
research Genetic Analysis of Androgen Receptors in Development and Disease
The document concludes that the androgen receptor's structure and function are complex, affecting how it regulates genes and is involved in diseases like prostate cancer.
research Mechanisms that regulate androgen receptor transcriptional activity
DHT enhances androgen receptor activity more than testosterone, and MAGE-11 influences this activity through specific interactions.
research Bicalutamide
research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content*
A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.